---
title: "Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295948762.md"
description: "Lifeward Ltd. reported Q2 2026 results with revenue up 15.7% YoY to $6.62M, driven by higher AlterG shipments and ReWalk sales in Europe. However, the company posted a net loss of ($11.52M) and diluted EPS of ($4.12), compared to a prior-year net loss of ($6.56M). Operational improvements included resolving AlterG supply constraints and launching ReWalk 7. The company also noted progress in reimbursement and market access, including CMS/Medicare recognition."
datetime: "2026-08-14T14:31:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295948762.md)
  - [en](https://longbridge.com/en/news/295948762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295948762.md)
generator: "portal-rs"
---

# Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary

Lifeward Ltd. reported results for the 2026 quarter with revenue up 15.7% year-over-year to $6.62M while the company recorded a net loss of ($11.52M) and diluted loss per share of ($4.12), compared with a net loss of ($6.56M) and loss per share of ($7.01) in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$6.62M

$5.72M

15.7%

Net income²

($11.52M)

($6.56M)

(75.5%)

Diluted EPS³

($4.12)

($7.01)

41.2%

*¹ Reported as “Revenues”. ² Reported as “Net loss”. ³ Reported as “Net loss per ordinary share, basic and diluted”.*

**Business Highlights**

-   Revenue growth was driven by higher AlterG shipments and stronger ReWalk sales in Europe.
-   Expanded channel partnerships, including an exclusive CorLife workers’ comp distributor and a Verita Neuro international distributor, to broaden access.
-   Product momentum included the launch of next‑gen ReWalk 7 (510k cleared March 2025) and progress integrating ORMD‑0801 and Skelable upper‑body technologies.
-   Operational recovery: AlterG supply constraints from Q1 were resolved, producing a meaningful Q2 recovery and improved commercial adoption.
-   Continued reimbursement and market-access gains, including CMS/Medicare progress with K1007 fee schedule recognition and a favorable ALJ ruling supporting Medicare coverage.

Original SEC Filing: Lifeward Ltd. \[ LFWD \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LFWD.US](https://longbridge.com/en/quote/LFWD.US.md)

## Related News & Research

- [Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth | LFWD Stock News](https://longbridge.com/en/news/295940947.md)
- [Ticketplus Ltd. GAAP EPS of $0.21, revenue of $12.61M](https://longbridge.com/en/news/296401649.md)
- [PulteGroup, Inc. $PHM Shares Sold by Milford Funds Ltd.](https://longbridge.com/en/news/295998603.md)
- [Knorex Ltd. reports FY results](https://longbridge.com/en/news/296441474.md)
- [1,000,000 Shares in Mattel, Inc. $MAT Bought by Serenity Capital Management PTE. LTD.](https://longbridge.com/en/news/296341699.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**